SPT1 Antibody
| Code | Size | Price |
|---|
| PSI-6303-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-6303-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
SPT1 Antibody: HSN1, LBC1, LCB1, SPT1, SPTI, HSAN1, Serine palmitoyltransferase 1, Long chain base biosynthesis protein 1, LCB 1
Application Note:
SPT1 antibody can be used for detection of SPT1 by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL.
Antibody validated: Western Blot in human samples and Immunohistochemistry in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples and Immunohistochemistry in human samples. All other applications and species not yet tested.
Background:
SPT1 Antibody: Serine palmitoyltransferase, which consists of two different subunits, is the key enzyme in sphingolipid biosynthesis. It converts L-serine and palmitoyl-CoA to 3-oxosphinganine with pyridoxal 5'-phosphate as a cofactor. SPT1 is the long chain base subunit 1 of mammalian serine palmitoyltransferase. SPT1 is not catalytically active but is necessary for the stabilization of the SPT2 subunit and anchoring the holoenzyme to the cytosolic face of the endoplasmic reticulum. Missense mutations in this gene have been identified in patients with hereditary sensory neuropathy type 1 (HSAN1). These mutations induce a shift in the substrate specificity of the holoenzyme, leading to the formation and accumulation of two neurotoxic sphingolipids.
Background References:
- Batheja AD, Uhlinger DJ, Carton JM, et al. Characterization of serine palmitoyltransferase in normal human tissues. J. Histochem. & Cytochem. 2003; 51:687-96.
- Hanada K, Hara T, Nishijima N, et al. A mammalian homolog of the yeast LCB1 encodes a component of serine palmitoyltransferase, the enzyme catalyzing the first step in sphingolipid synthesis. J. biol. Chem. 1997; 272:32108-14.
- Yasuda S, Nishijima N, and Hanada K. Localization, topology, and function of the LCB1 subunit of serine palmitoyltransferase in mammalian cells. J. Biol. Chem. 2003; 278:4176-83.
- Penno A, Reilly MM, Houlden H, et al. Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids. J. Biol. Chem. 2010; 285:11178-87.
Buffer:
SPT1 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Mouse: (88%), Bovine: (76%)
Immunogen:
SPT1 antibody was raised against a 17 amino acid synthetic peptide near the carboxy terminus of human SPT1.
The immunogen is located within amino acids 380 - 430 of SPT1.
The immunogen is located within amino acids 380 - 430 of SPT1.
NCBI Gene ID #:
10558
NCBI Official Name:
serine palmitoyltransferase, long chain base subunit 1
NCBI Official Symbol:
SPTLC1
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 51 kDa
Observed: 51 kDa
Observed: 51 kDa
Protein Accession #:
NP_6406
Protein GI Number:
5454084
Purification:
SPT1 Antibody is affinity chromatography purified via peptide column.
Research Area:
Homeostasis
SPECIFICITY:
At least two isoforms of SPT1 are known to exist; this antibody will detect only isoform a. SPT1 antibody is predicted to not cross-react with SPT2.
Swissprot #:
O15269
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | SPT1 Peptide | PSI-6303P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|